Full Press Release Details
BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C.
BBIO
BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C
Key Takeaway: BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C
Price reaction · baseline $40.45 (2024-01-02 close) · hit after-hours · 1 other BBIO headline(s) in the window, move may be shared
day 0 close
-6.4%
day 1 · peak
-8.7%
day 3
-4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis